Form D · Biotechnology

Velicept Therapeutics, Inc.

Wayne, PA · CIK 0001659819

Offering snapshot reported Nov 19, 2019 · SEC filing

Reported sold
$6M
Offering amount: $9.2M
Investors reported
5
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Nov 5, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 19, 2019Initial$6,000,000No comparison5SEC filing
Jul 18, 2018Initial$15,508,713No comparison16SEC filing
Apr 20, 2017Amendment$18,410,010$6,381,434vs Dec 1, 201525SEC filing
Dec 1, 2015Initial$12,028,576No comparison24SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-353767

Source: Form D, filed Nov 19, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Bennethum Director
Cory S. Freedland Director
Cory Freedman Director
Douglas Gessl Executive
Doug Gessl Executive
David Hirsch Director
David Hirsch, M.D. Director
Aidan King Director
Aidan King, Mba, Cfa Director
Jill Becker Mast Director
Scott Morenstein Director
Stephen Tullman Director
James C. Walker Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
640 Lee Road, Suite 119
Wayne, PA, 19087
Phone: 484-318-2988